About
Laura is an associate in the Life Sciences Transactions team of our New York office. She advises companies in the healthcare, pharmaceutical and biotech space on a variety of transactions, including mergers and acquisitions, licensing agreements, and commercial agreements. Prior to joining Freshfields, Laura worked at a global law firm where she represented clients in complex trade secret and patent litigation matters involving diverse technologies.
Connect
VCARD
Additional Information
- Basilea Pharmaceutica on its license from Venatorx Pharmaceuticals to obtain the global rights to ceftibuten-ledaborbactam etzadroxil, a clinical phase 3-ready oral beta-lactam/beta-lactamase inhibitor (BL/BLI) combination for the potential treatment of complicated urinary tract infections.
- Cullinan Therapeutics on its license from Genrix Bio for the global (ex-Greater China) rights to velinotamig, a clinical-stage BCMAxCD3 bispecific T cell engager, for development in autoimmune diseases
- Merck on its acquisition of Verona Pharma plc for a total transaction value of approximately $10 billion.
- Sanofi S.A. on its acquisition of Vigil Neuroscience, a publicly traded clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases.
- Strava on its acquisition of Runna.
- Novartis in its global license agreement with Monte Rosa Therapeutics for VAV1-directed molecular glue degraders.
- CVC on its $925m carve-out acquisition of Therakos from Mallinckrodt.
- Grünenthal on its acquisition of Valinor Pharma and its product Movantik® (naloxegol).
- SERB Pharmaceuticals on its acquisition of RSDL® (Reactive Skin Decontamination Lotion) kit from Emergent BioSolutions Inc.
- Johnson & Johnson on its $13.1 billion acquisition of Shockwave Medical, Inc.
Laura Zhu
Associate
New York Office
3 World Trade Center
175 Greenwich Street, 51st Floor
10007 New York